Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and Bupropion for Binge-Eating Disorder and Obesity
NCT03946111Phase 3Completed
- Sponsor
- Yale University
- Start
- Aug 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) and obesity comparing Naltrexone/Bupropion with Placebo (2 arms). Primary endpoints: Change in Binge-Eating Frequency at 60 weeks and Percent Change in Weight at 60 weeks. Started Aug 2019; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
binge eating disorder (BED)obesity
Beyond the preview
Go deeper on NCT03946111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946111.